Anixa Biosciences' (ANIX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX - Free Report) in a report published on Tuesday morning,Benzinga reports. The brokerage currently has a $7.00 price objective on the stock. HC Wainwright also issued estimates for Anixa Biosciences' Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.40) EPS.

Other research analysts have also issued reports about the stock. D. Boral Capital reissued a "buy" rating and set a $10.00 price objective on shares of Anixa Biosciences in a report on Wednesday, January 22nd. Maxim Group began coverage on shares of Anixa Biosciences in a report on Friday, March 21st. They set a "buy" rating and a $10.00 price target for the company.

Anixa Biosciences Trading Down 3.6 %

Shares of ANIX stock traded down $0.11 during trading hours on Tuesday, hitting $2.97. The company's stock had a trading volume of 81,233 shares, compared to its average volume of 97,441. The business has a fifty day moving average of $2.97 and a 200-day moving average of $3.00. The stock has a market cap of $95.63 million, a price-to-earnings ratio of -7.62 and a beta of 0.86. Anixa Biosciences has a twelve month low of $2.07 and a twelve month high of $4.20.

Remove Ads

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.10) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.10). On average, equities analysts expect that Anixa Biosciences will post -0.41 EPS for the current fiscal year.

Insider Activity

In other Anixa Biosciences news, Director Lewis H. Titterton, Jr. bought 10,000 shares of the business's stock in a transaction on Friday, January 17th. The shares were bought at an average cost of $2.57 per share, for a total transaction of $25,700.00. Following the transaction, the director now owns 922,334 shares in the company, valued at approximately $2,370,398.38. This trade represents a 1.10 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Amit Kumar bought 43,000 shares of the stock in a transaction on Wednesday, January 15th. The shares were acquired at an average cost of $2.23 per share, with a total value of $95,890.00. Following the acquisition, the chief executive officer now directly owns 559,925 shares in the company, valued at approximately $1,248,632.75. This trade represents a 8.32 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 75,289 shares of company stock valued at $177,021. 25.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in Anixa Biosciences during the 3rd quarter worth approximately $34,000. Millennium Management LLC acquired a new stake in shares of Anixa Biosciences in the fourth quarter valued at approximately $26,000. Renaissance Technologies LLC lifted its holdings in Anixa Biosciences by 36.5% during the 4th quarter. Renaissance Technologies LLC now owns 14,573 shares of the company's stock valued at $34,000 after purchasing an additional 3,900 shares during the last quarter. Prosperity Wealth Management Inc. acquired a new stake in shares of Anixa Biosciences during the 4th quarter worth about $54,000. Finally, Jane Street Group LLC bought a new stake in shares of Anixa Biosciences during the fourth quarter worth approximately $67,000. 29.13% of the stock is currently owned by institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.